Loading patent…
AssigneeFidia S.p.A.
InventorsFrancesco della Valle, Aurelio Romeo, Silvana Lorenzi
Estimating the term…
Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections. In addition, pharmaceutical preparations for topical administration are provided containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.
A pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of a partial or a stoichiometrically neutral salt of hyaluornic acid or a molecular weight fraction thereof with at least one pharmacologically active substance of a basic nature suitable for topical administration and which is capable of being absorbed intradermally or thorugh the nasal or rectal mucosa, together with an excipient suitable for topical administration.
A pharmaceutical composition which comprises hyaluronic acid or a pharmaceutically acceptable salt thereof and a non-steroid anti-inflammatory agent or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition which comprises hyaluronic acid or a pharamaceutically acceptable salt thereof and a non-steroid anti-inflammatory agent.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Carbohydrates; Sugars; Derivatives thereof: polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic…
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
Galenical forms characterised by the site of application: eye, e.g. artificial tears
Term ended 24 Nov 2009 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to specific molecular weight fractions of hyaluronic acid (hereinafter referred to as "HA" or HY) which have therapeutic applications and which are non-inflammatory when utilized. One of the HA fractions of this invention is particularly useful for facilitating wound healing, while the second HA fraction is particularly useful for intraocular use to sbustitute for endobulbar fluids or for intraarticular injection for use in treating damaged bone joints.
The invention further relates to the use of the HA fractions as vehicles for ophthalmic drugs. The use of HA as a vehicle provides a formulation compatible with the corneal epithelium and enhances the activity of some ophthalmic drugs.
Furthermore, the invention relates to new medicaments for topical use and more precisely to medicaments containing:
FIG. 1 is a graph showing the different fractions of hyaluronic acid which have been identified by the present inventors.
I. Molecular Weight Fractions of HA.
As discussed above, previous investigations of HA, as exemplified by the Balazs patent, have been directed to utilizing high molecular weight fractions with an average molecular weight of greater than 750,000. The present inventors have isolated and characterized two new fractions of HA, one having a low molecular weight and another having a medium ranged average molecular weight, which are of a high degree of purity and do not have inflammatory activity. These new fractions of HA can be obtained from various connective tissues which contain extractable amounts of hyaluronic acid. The specific fractions of the invention are differentiated and separated according to molecular filtration techniques.
The first fraction isolated by the inventors has been named HYALASTINE, and has an average molecular weight of from about 50,000 to about 100,000. This HYALASTINE fraction has been determined to be suitable for therapeutic, veterinary and human use because of its wound healing activity. The second fraction isolated by the inventors has been labelled HYALECTIN, and has an average molecular weight of about 500,000 to about 730,000. This HYALECTIN fraction is suitable for use in ocular surgery as a substitute for endobulbar liquids and for veterinary and human therapy in traumatic and degenerative diseases of the joints.